The Scottish Medicines Consortium has rejected Esomeprazole (Nexium)® for use in Scotland following two separate assessments.
The first assessment concluded that esomeprazole is not recommended for the healing of gastric ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy.
The second assessment concluded that esomeprazole is not recommended for the prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory (NSAID) therapy in patients at risk.
In both cases the conclusion was based on the lack of comparative data with other Proton Pump Inhibitors (PPI) and the fact that an economic case had not been demonstrated.
Action: Lansoprazole is currently the first line choice where a PPI is indicated. PPIs have been covered in the Prescribing Formulary category in December 2005 and updated more recently in March 2006.
|« Blood glucose meter safety warning||Current Problems in Pharmacovigilance »|